MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  05/20 04:03:28 pm EDT
93.55 USD   +1.59%
05/20Merck's Keytruda Receives Positive EMA Panel Opinion as Adjuvant Therapy in Skin Cancer
MT
05/20Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
BU
05/20Merck Gets CHMP Backing for Expanded Keytruda Use in Melanoma
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:

- sale of pharmaceutical products (73.2%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;

- sale of vaccines (16.4%);

- sale of animal health products (9.8%);

- other (0.6%).

Net sales are distributed geographically as follows: the United States (43.8%), Europe/Middle East/Africa (28.3%), China (7.6%), Japan (7%), Asia/Pacific (6%), Latin America (4.7%) and other (2.6%).

Number of employees : 68 000 people.
Sales per Business
20202021Delta
Pharmaceutical43 021.0089.6%42 754.0087.8% -0.62%
Animal Health4 703.009.8%5 568.0011.4% +18.39%
Other247.000.5%382.000.8% +54.66%
USD in Million
Sales per region
20202021Delta
United States21 027.0043.8%22 425.0046% +6.65%
Europe, Middle East and Africa13 600.0028.3%13 341.0027.4% -1.9%
China3 624.007.6%4 378.009% +20.81%
Japan3 376.007%2 726.005.6% -19.25%
Asia Pacific2 864.006%2 407.004.9% -15.96%
Latin America2 274.004.7%2 206.004.5% -2.99%
Other1 229.002.6%1 221.002.5% -0.65%
USD in Million
Managers
Name Title Age Since
Robert Davis President, Chief Executive Officer & Director 54 2021
Caroline Litchfield Chief Financial Officer & Executive Vice President 52 2021
Dave Williams EVP, Chief Information & Digital Officer - -
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP - 2021
Peter Dannenbaum Vice President-Investor Relations - 2019
Kelly E. W. Grez Secretary - -
Richard R. DeLuca Executive Vice President & President-Animal Health 58 2013
Eric H. Rubin, Dr. Senior VP-Global Clinical Oncology 62 -
Denise Williams Vice President - -
Sanat Chattopadhyay EVP & President-Merck Manufacturing Division - -
Members of the board
Name Title Age Since
Kenneth Frazier Executive Chairman 66 2021
Thomas Henry Glocer Lead Independent Director 61 2021
Patricia Russo Independent Director 68 1995
Peter C. Wendell Independent Director 70 2003
Pamela J. Craig Independent Director 64 2015
Paul B. Rothman, Dr. Independent Director 63 2015
Inge Thulin Independent Director 67 2018
Mary Ellen Coe Independent Director 54 2019
Kathy Warden Independent Director 49 2020
Christine E. Seidman, Dr. Independent Director 68 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,577,532,250 2,526,741,728 70.6% 1,048,727,225 29.3% 70.6%
Shareholders
NameEquities%
The Vanguard Group, Inc. 205,866,415 8.14%
Capital Research & Management Co. 138,704,087 5.49%
SSgA Funds Management, Inc. 118,322,390 4.68%
BlackRock Fund Advisors 56,794,341 2.25%
Wellington Management Co. LLP 45,700,904 1.81%
Geode Capital Management LLC 44,407,613 1.76%
Charles Schwab Investment Management, Inc. 30,079,662 1.19%
Northern Trust Investments, Inc.(Investment Management) 29,735,605 1.18%
Massachusetts Financial Services Co. 28,844,244 1.14%
Norges Bank Investment Management 23,786,901 0.94%
Holdings
NameEquities%Valuation
NGM BIOPHARMACEUTICALS, INC. (NGM) 12,955,016 16.6% 161,678,600 USD
IMAGO BIOSCIENCES, INC. (IMGO) 1,193,046 3.54% 19,506,302 USD
SUTRO BIOPHARMA, INC. (STRO) 2,723,509 5.87% 16,368,289 USD
ENTRADA THERAPEUTICS, INC. (TRDA) 1,739,768 5.55% 10,403,813 USD
LAVA THERAPEUTICS N.V. (LVTX) 1,082,679 4.20% 4,406,504 USD
4D PHARMA PLC (DDDD) 8,315,023 4.61% 4,102,715 USD
XILIO THERAPEUTICS, INC. (XLO) 1,096,885 3.99% 3,872,004 USD
YUMANITY THERAPEUTICS, INC. (YMTX) 526,999 4.87% 579,699 USD
Markets and indexes
- International Market
- DJIA / S&P 100, S&P 500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50
Company contact information
Merck & Co., Inc.
2000 Road Galloping Hill
PO Box 100
NJ 07033 Kenilworth, New Jersey

Phone : +1 (908) 740-4000
Fax :
web site : https://www.merck.com/
Brand Portfolio
In partnership withAllbrands.markets
More brands of Merck & Co., Inc.
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
MERCK & CO., INC.22.06%236 570
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707
NOVO NORDISK A/S3.58%245 099
ASTRAZENECA PLC20.93%202 681
NOVARTIS AG8.00%193 025
BRISTOL-MYERS SQUIBB COMPANY22.20%162 213
SANOFI15.49%134 759
AMGEN INC.10.01%132 214
GLAXOSMITHKLINE PLC9.80%111 286
BAYER AG35.62%66 062
DAIICHI SANKYO CO., LTD.13.20%49 636
CHUGAI PHARMACEUTICAL CO., LTD-5.33%45 478
TAKEDA PHARMACEUTICAL COMPANY LIMITED18.87%45 016
JIANGSU HENGRUI MEDICINE CO., LTD.-40.37%28 822
ASTELLAS PHARMA INC.4.92%27 643
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-30.05%27 566
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-16.16%20 770